Fate Therapeutics, Inc.

News that oncologist Vinay Prasad will be the new head of the US Food and Drug Administration’s Center for Biologics Evaluation and Research (CBER) division sent biopharma shares tumbling on 6 May, as

Radionetics Oncology , a three-year-old start-up that has raised $82.5m to date, landed a sweet deal with Eli Lilly and Company , with the big pharma paying $140m up front for an exclusive right to b

Pfizer Inc. held a 32% stake in Haleon plc after the consumer health business spun out of GSK plc in 2022, but through a sale of stock on 19 March Pfizer reduced its stake to 22.6% and garnered $

There’s a new CAR-T kid on the block. A young Indian cell and gene therapy company, Immunoadoptive Cell Therapy (ImmunoACT), has delivered the country’s first such cell therapy for the treatment of re